title: Myocardial viability in chronic ischemic heart disease: comparison of contrast-enhanced magnetic resonance imaging with (18)F-fluorodeoxyglucose positron emission tomography.
abstract: OBJECTIVE
  We sought to compare contrast-enhanced magnetic resonance imaging (ceMRI) with nuclear metabolic imaging for the assessment of myocardial viability in patients with chronic ischemic heart disease and left ventricular (LV) dysfunction.
  
  
  BACKGROUND
  Contrast-enhanced MRI has been shown to identify scar tissue in ischemically damaged myocardium.
  
  
  METHODS
  Twenty-six patients with chronic coronary artery disease and LV dysfunction (mean ejection fraction 31 +/- 11%) underwent (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET), technetium-99m tetrofosmin single-photon emission computed tomography (SPECT), and ceMRI. In a 17-segment model, the segmental extent of hyperenhancement (SEH) by ceMRI, defined as the relative amount of contrast-enhanced tissue per myocardial segment, was compared with segmental FDG and tetrofosmin uptake by PET and SPECT.
  
  
  RESULTS
  In severely dysfunctional segments (n = 165), SEH was 9 +/- 14%, 33 +/- 25% (p < 0.05), and 80 +/- 23% (p < 0.05) in segments with normal metabolism/perfusion, metabolism/perfusion mismatch, and matched defects, respectively. Segmental glucose uptake by PET was inversely correlated to SEH (r = -0.86, p < 0.001). By receiver operator characteristic curve analysis, the area under the curve was 0.95 for the differentiation between viable and non-viable segments. At a cutoff value of 37%, SEH optimally differentiated viable from non-viable segments defined by PET. Using this threshold, the sensitivity and specificity of ceMRI to detect non-viable myocardium as defined by PET were 96% and 84%, respectively.
  
  
  CONCLUSIONS
  Contrast-enhanced MRI allows assessment of myocardial viability with a high accuracy, compared with FDG-PET, in patients with chronic ischemic heart disease and LV dysfunction.
authors.affiliation: Medical Clinic I, University Hospital, Aachen, Germany.
authors.forename: Harald P
authors.initials: HP
authors.lastname: Kühl
authors.forename: Aernout M
authors.initials: AM
authors.lastname: Beek
authors.forename: Arno P
authors.initials: AP
authors.lastname: van der Weerdt
authors.forename: Mark B M
authors.initials: MB
authors.lastname: Hofman
authors.forename: Cees A
authors.initials: CA
authors.lastname: Visser
authors.forename: Adriaan A
authors.initials: AA
authors.lastname: Lammertsma
authors.forename: Nicole
authors.initials: N
authors.lastname: Heussen
authors.forename: Frans C
authors.initials: FC
authors.lastname: Visser
authors.forename: Albert C
authors.initials: AC
authors.lastname: van Rossum
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D003287:Contrast Media; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000175:diagnosis* / Q000000981:diagnostic imaging; D019275:Radiopharmaceuticals; D012107:Research Design; D012680:Sensitivity and Specificity; D014055:Tomography, Emission-Computed / Q000379:methods
chemical_list: D003287:Contrast Media; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18